Alpha-1 Antitrypsin Deficiency: A Rare Disease? - PubMed

Alpha-1 Antitrypsin Deficiency: A Rare Disease? - PubMed

Alpha-1 Antitrypsin Deficiency: A Rare Disease?

Roxana Cortes-Lopez 1, Igor Barjaktarevic 2

Affiliations 

• PMID: 32572624
 
• DOI: 10.1007/s11882-020-00942-4

Abstract

Purpose of review: Commonly categorized as a rare disease, alpha-1 antitrypsin deficiency (AATD) is neither rare, when compared to many other genetic disorders, nor an actual disease, but rather a predisposition toward a wide variety of diseases. It is one of the most common genetic disorders which can lead to a spectrum of clinical manifestations, ranging from no symptoms to progressively debilitating systemic disease, most commonly affecting the lung and liver. It is therefore imperative for clinicians to recognize and be familiar with the spectrum of presentations, methods of diagnosis, and clinical management of AATD. It is also imperative for scientists to recognize the potential for progress in the management of this disorder.

Recent findings: This review focuses on the current state of knowledge of AATD, including the wide range of presentations, diagnosis, and clinical management. In addition to the clinical implications of severe AATD, we discuss the relevance of heterozygous state with mild or moderate AATD in the development of both lung and liver disease. While our understanding of the multiple roles of alpha-1 antitrypsin (AAT) is on the rise, with appreciation of its immunomodulatory, anti-infective, and anti-inflammatory properties, this knowledge has yet to impact our ability to predict outcomes. We discuss nuances of augmentation therapy and review novel therapeutic approaches currently under investigation. With the expanding knowledge about the complexities of AAT function and its clinical relevance, and with the increasing ability to diagnose early and intervene on AATD, it should be our goal to change the perception of AATD as a correctable inherited disorder rather than a fatal disease.

Keywords: Alpha-1 antitrypsin deficiency; Augmentation therapy; Chronic obstructive pulmonary disease; Emphysema; PiZZ; Protease inhibitor; SERPINA1.

Similar articles

• Alpha-1 Antitrypsin Deficiency.

  Stoller JK, Hupertz V, Aboussouan LS.2006 Oct 27 [updated 2020 May 21]. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2020.PMID: 20301692 Free Books & Documents. Review.
• Long-term clinical outcomes following treatment with alpha 1-proteinase inhibitor for COPD associated with alpha-1 antitrypsin deficiency: a look at the evidence.

  Rahaghi FF, Miravitlles M.Respir Res. 2017 May 30;18(1):105. doi: 10.1186/s12931-017-0574-1.PMID: 28558837 Free PMC article. Review.
• Hereditary alpha-1-antitrypsin deficiency and its clinical consequences.

  Fregonese L, Stolk J.Orphanet J Rare Dis. 2008 Jun 19;3:16. doi: 10.1186/1750-1172-3-16.PMID: 18565211 Free PMC article. Review.
• The important role of primary care providers in the detection of alpha-1 antitrypsin deficiency.

  Lascano JE, Campos MA.Postgrad Med. 2017 Nov;129(8):889-895. doi: 10.1080/00325481.2017.1381539. Epub 2017 Oct 5.PMID: 28929906 Review.
• Using antisense technology to develop a novel therapy for α-1 antitrypsin deficient (AATD) liver disease and to model AATD lung disease.

  Guo S, Booten SL, Watt A, Alvarado L, Freier SM, Teckman JH, McCaleb ML, Monia BP.Rare Dis. 2014 Mar 12;2:e28511. doi: 10.4161/rdis.28511. eCollection 2014.PMID: 25054094 Free PMC article.